Cumberland Pharmaceuticals Inc. CPIX Cash Flow

Cumberland pharmaceuticals inc. (CPIX)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities:
Net income (loss)
-1,065	-972	-1,966	-566	-40	-2,237	-1,664	-745	-2,392	-821	-757	-5,177	-1,293	-769	95	-60	-268	128	121	394	26	648	729	709	275	-1,511	-832	-648	841	1,793	1,862	1,736	413	908	1,838	2,168	711
Discontinued operations
818	-	-	-	1,147	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss) from continuing operations
-1,883	-	-	-	-1,187	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:
Depreciation and amortization expense
1,152	1,125	1,104	1,098	1,076	874	713	701	692	673	659	652	661	611	613	589	582	568	534	581	561	605	583	405	395	384	306	319	290	237	223	223	217	238	274	264	262
Deferred tax expense
0	21	0	0	43	81	0	0	0	-87	0	3,535	758	-43	129	329	204	446	20	23	0	-	-	-	-	-1,503	-141	0	65	-829	0	0	0	-	-	-	-
Share-based compensation
264	378	346	396	364	359	339	326	339	265	297	296	254	228	215	233	174	195	-122	303	246	219	216	199	125	194	175	176	128	79	165	176	214	-	-	-	-
Stock-based compensation - nonemployees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19
Stock-based compensation - employees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	147
Decrease in non-cash contingent consideration
543	-681	359	52	269	81	0	0	0	0	0	-1	92	-119	-72	-407	-427	-379	156	295	18	575	365	523	188	559	-527	-463	478	1,584	1,321	663	191	-301	1,140	1,375	141
Noncash interest expense
11	11	8	17	10	55	10	15	18	17	9	24	26	23	23	23	13	13	13	11	8	26	0	6	6	12	0	6	6	8	4	6	6	6	7	99	24
Noncash investment gains
0	-	-91	81	44	-	13	74	43	-	29	23	-4	-	17	4	46	-	35	24	20	-	43	-40	-141	-	-72	-51	-10	-	64	25	8	-	-	-	-
Net changes in assets and liabilities affecting operating activities:
Accounts receivable
-2,014	2,484	-1,130	-778	1,361	789	1,249	-495	-2,093	1,189	1,098	-3,618	2,395	657	2,121	-271	-1,254	278	-9	633	-329	208	-718	597	886	336	223	-1,996	-49	549	475	528	-2,619	2,577	-314	-325	0
Inventories
-706	-646	-784	-935	-494	-149	-919	683	-76	880	303	457	-275	388	61	847	-196	64	-589	161	-966	-530	-866	-425	289	287	-658	102	-226	-1,293	195	1,311	230	-1,099	-578	-369	139
Other current assets and other assets
-1,093	783	-53	-6	-134	254	-162	-203	-600	646	346	-51	132	314	1,143	-436	534	23	662	-292	-130	-343	653	382	319	-294	237	-68	8	-579	1,054	-151	324	-	-	-	-
Other current assets and other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,241	125	-126
Accounts payable and other current liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,614	1,901	2,033	-23
Accounts payable and other current liabilities
-2,394	-	-594	-1,606	474	-	-864	523	-1,254	-	2,561	-704	-1,216	-	2,356	-2,577	-1,483	-	191	1,516	-251	-	127	469	1,696	-	-1,234	-2,200	492	-	2,816	1,645	-282	-	-	-	-
Other long-term liabilities
-865	-522	135	10	-353	-302	6	32	103	173	-0	147	92	119	131	57	78	-64	-18	24	55	56	-3	83	25	74	75	-8	46	711	-58	-775	178	-	-	-	-
Net cash provided by (used in) operating activities from continuing operations
-444	-	-	-	-618	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Discontinued operations
1,332	-	-	-	232	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other long-term liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2
Net cash provided by (used in) operating activities
888	857	734	1,850	-385	3,723	-1,640	794	235	-459	992	-2,530	1,439	819	293	-1,142	598	1,323	485	2,034	2,033	2,735	2,139	835	982	-192	-853	121	1,670	1,987	1,902	634	2,610	1,030	2,756	3,951	983
Cash flows from investing activities:
Additions to property and equipment
22	79	77	61	27	283	40	36	94	103	29	19	123	32	27	-2	73	46	34	-46	108	12	102	18	29	4	23	8	60	171	114	146	32	15	136	71	34
Purchases of marketable securities
0	2,117	0	1,811	7,816	-1,279	3,935	1,764	15,151	350	827	409	792	1,829	684	1,793	1,166	2,327	1,155	2,546	1,500	452	500	2,504	750	0	0	1,401	2,970	3,011	493	2,363	15,992	-	-	-	-
Proceeds from sale of marketable securities
0	-	7,122	2,080	6,483	-	9,218	2,646	4,257	-	7,158	1,545	941	-	667	2,098	910	-	888	2,298	2,497	-	734	1,171	1,096	-	277	794	686	-	243	145	0	-	-	-	-
Cash paid for acquisitions
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	2,000	-	0	0	0	-	-	-	-	-	-	-	-
Additions to intangible assets
548	274	102	31	363	2,407	818	60	532	371	87	299	453	445	476	452	624	163	-347	677	2,062	1,483	885	343	388	4,861	770	868	961	450	1,101	338	180	39	94	26	20
Net cash used in investing activities
-571	1,903	6,942	-4,823	-1,723	-21,411	4,424	784	-11,522	2,911	6,213	816	-429	-1,495	-522	-144	-953	-338	46	-879	-1,173	-1,513	-753	-1,695	-2,072	233	-516	-1,483	-3,305	1,197	-1,465	-2,703	-16,206	-55	-230	-97	-54
Cash flows from financing activities:
Borrowings on line of credit
18,500	20,000	20,000	17,000	19,000	20,000	12,000	12,000	12,000	9,800	8,000	6,700	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-750	250	-	-	-	-
Repayments on line of credit
18,500	21,500	20,000	17,000	19,000	12,000	12,000	12,000	9,800	8,000	6,700	4,100	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	3,999	666	666
Proceeds from sales of common stock, net of offering costs
-	-	-	-	-	-	0	0	200	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments of deferred equity offering costs
-	-	-	-	-	135	0	0	248	27	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sales of shares of common stock, net of offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	9	12	0	0	0	0	0	0	0	-41	37	34	0	545	-51	158	90	433
Cash payment of contingent consideration
260	124	223	177	507	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repurchase of subsidiary shares from noncontrolling interest
800	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repurchase of common shares
442	901	1,373	507	712	496	431	935	1,016	830	1,103	1,244	545	641	190	709	979	669	1,313	1,644	1,711	1,576	1,158	660	919	882	756	1,219	1,942	1,260	3,264	1,215	2,346	1,362	1,332	779	772
Excess tax (expense) benefit derived from exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-119	-72	-407	-427	-379	156	295	18	575	365	523	188	559	-527	-463	478	1,584	1,321	663	191	-301	1,140	1,375	141
Net cash used in financing activities
-1,503	-1,525	-1,649	-685	-1,220	7,368	-431	-935	1,136	941	196	1,355	-545	-360	-62	683	-1,407	-1,097	-1,156	-1,259	-1,681	-1,000	-792	862	-731	-5,182	-2,283	-182	-1,505	362	-1,908	-1,301	-1,359	-1,450	-1,283	19	-864
Net decrease in cash and cash equivalents
-1,185	-	-	-	-3,329	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net decrease in cash and cash equivalents
-	-	-	-	-	-	2,352	643	-10,149	-	7,402	-358	463	-1,035	-290	-603	-1,762	-113	-624	-104	-821	221	593	2	-1,821	-5,141	-3,653	-1,544	-3,139	3,547	-1,471	-3,370	-14,955	-475	1,242	3,873	64
Supplemental non-cash operating, investing and financing activities:
Noncash investing and financing activities:
Recognition of operating lease assets and liabilities through adoption of ASC 842
0	0	0	0	3,629	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net change in unpaid additions to intangibles, property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	524	560	-110	-	-19	89	160	-	21	-9	82	-	-	-	-
Change in unpaid fixed asset additions
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26